ANI Pharmaceuticals (ANIP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Oren ...

Truist Financial analyst Les Sulewski maintained a Hold rating on ANI Pharmaceuticals (ANIP – Research Report) today and set a price target of $62.00. The company’s shares closed last Friday at $61.44 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Short Sellers. In this article, we are ...

ANI Pharmaceuticals ranks in the middle for consensus rating among its peers. It is at the bottom for revenue growth. In terms of gross profit, it is at the top among its peers. However, for return on ...

BAUDETTE, Minn. (AP) — BAUDETTE, Minn. (AP) — ANI Pharmaceuticals Inc. (ANIP) on Friday reported a third-quarter loss of $24.2 million, after reporting a profit in the same period a year earlier. The ...

ANI Pharmaceuticals (NASDAQ:ANIP) is scheduled to announce Q3 earnings results on Friday, November 8th, before market open. The consensus EPS Estimate is $1.09 (-14.2% Y/Y) and the consensus Revenue ...

ANI Pharmaceuticals (NASDAQ:ANIP) traded higher in the premarket trading on Friday after Piper Sandler launched its coverage with an overweight recommendation and a $68 per share target ...

SAN RAFAEL, Calif., Nov. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at three upcoming investor conferences. BioMarin ...